test

Scott Smith

@Acuta Capital Partners, Llc

Latest period2024 - Q3ReportedManaged Assets$123.464MTotal holdings41
Assets growth rate3.99%Assets growth rate (2-Q avg)-9.44%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Acuta Capital Partners, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 41 positions.

Assets under management

The assets under management (AUM) of Acuta Capital Partners, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 123.464M in assets, with a quarterly growth rate of 3.99% and a 2-quarter average growth rate of -9.44%. The portfolio is managed by Scott Smith, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
PCVXVaxcyte Inc
Recent Activity
Increased 22.65%
12.54%
$15.472M
135,400 shares@ $114.27 avg price
OCULOcular Therapeutix Inc
Recent Activity
Decreased -57.05%
8.39%
$10.354M
1.19M shares@ $8.71 avg price
TRMLTourmaline Bio Inc
Recent Activity
Increased 23.18%
6.92%
$8.538M
332,095 shares@ $25.71 avg price
INSMInsmed Inc
Recent Activity
Increased 49.1%
6.36%
$7.848M
107,500 shares@ $73.0 avg price
ELVNEnliven Therapeutics Inc
Recent Activity
Decreased -25.47%
6.14%
$7.569M
296,368 shares@ $25.55 avg price
CRNXCrinetics Pharmaceuticals In
Recent Activity
Decreased -2.54%
5.46%
$6.73M
131,700 shares@ $51.1 avg price
ACLXArcellx Inc
Recent Activity
Increased 47.16%
4.21%
$5.186M
62,100 shares@ $83.51 avg price
MREOMereo Biopharma Group Plc
Recent Activity
Increased 86.22%
4.2%
$5.181M
1.261M shares@ $4.11 avg price
RVMDRevolution Medicines Inc
Recent Activity
Decreased -18.79%
3.97%
$4.898M
108,000 shares@ $45.35 avg price
TSHATaysha Gene Therapies Inc
Recent Activity
Decreased -9.09%
3.45%
$4.259M
2.119M shares@ $2.02 avg price